News & Updates

Adding capecitabine to adjuvant chemotherapy containing docetaxel, epirubicin and cyclophosphamide significantly improves 15-year overall survival (OS) in patients with early breast cancer, results of the phase III FinXX trial (Finland Capecitabine Trial) have shown.

Medication with acetylcholinesterase inhibitors (AChEI) increases the risk of lung cancer among older patients and those with several comorbidities, reports a recent study.

Development of type 2 diabetes (T2D) is more likely to occur among patients with thyroid cancer who underwent thyroidectomy than matched controls, a Korea study has shown. In addition, a U-shaped dose-dependent relationship exists between the levothyroxine dosage and T2D risk.

In patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations*, combining niraparib with abiraterone acetate plus prednisone (AAP) in the first-line setting improved radiographic progression-free survival (rPFS) and other outcomes, results of the phase III MAGNITUDE study showed.

Weight loss during adulthood, particularly among overweight or obese individuals, is associated with a reduction in the risk of developing distal colorectal adenomas – a precursor to colorectal cancer, whereas weight gain increased its risk, according to findings from the PLCO* Cancer Screening Trial.